International consensus on preliminary definitions of improvement in adult and juvenile myositis.
about
Immunosuppressant and immunomodulatory treatment for dermatomyositis and polymyositisDevelopments in the classification and treatment of the juvenile idiopathic inflammatory myopathiesMeasures of adult and juvenile dermatomyositis, polymyositis, and inclusion body myositis: Physician and Patient/Parent Global Activity, Manual Muscle Testing (MMT), Health Assessment Questionnaire (HAQ)/Childhood Health Assessment Questionnaire (C-A systematic review of studies that aim to determine which outcomes to measure in clinical trials in childrenClinical characteristics of anti-SAE antibodies in Chinese patients with dermatomyositis in comparison with different patient cohorts.The COMET Handbook: version 1.0.Developing a provisional, international minimal dataset for Juvenile Dermatomyositis: for use in clinical practice to inform research.The Paediatric Rheumatology International Trials Organisation provisional criteria for the evaluation of response to therapy in juvenile dermatomyositis.Validation of the auto-inflammatory diseases activity index (AIDAI) for hereditary recurrent fever syndromes.Rituximab in the treatment of refractory adult and juvenile dermatomyositis and adult polymyositis: a randomized, placebo-phase trial.Juvenile dermatomyositis: new developments in pathogenesis, assessment and treatment.Methods of formal consensus in classification/diagnostic criteria and guideline development.A randomized, pilot trial of etanercept in dermatomyositis.Development of an internationally agreed minimal dataset for juvenile dermatomyositis (JDM) for clinical and research use.Consensus treatments for moderate juvenile dermatomyositis: beyond the first two months. Results of the second Childhood Arthritis and Rheumatology Research Alliance consensus conferenceLimited effects of high-dose intravenous immunoglobulin (IVIG) treatment on molecular expression in muscle tissue of patients with inflammatory myopathies.Treating refractory dermatomyositis or polymyositis with adrenocorticotropic hormone gel: a retrospective case series.Serum level of soluble CX3CL1/fractalkine is elevated in patients with polymyositis and dermatomyositis, which is correlated with disease activityNovel assessment tools to evaluate clinical and laboratory responses in a subset of patients enrolled in the Rituximab in Myositis trial.Proposal for a Candidate Core Set of Fitness and Strength Tests for Patients with Childhood or Adult Idiopathic Inflammatory MyopathiesChanges in novel biomarkers of disease activity in juvenile and adult dermatomyositis are sensitive biomarkers of disease courseClinical assessment in juvenile dermatomyositis.Research priorities in pediatric rheumatology: The Childhood Arthritis and Rheumatology Research Alliance (CARRA) consensusMagnetic resonance measurement of muscle T2, fat-corrected T2 and fat fraction in the assessment of idiopathic inflammatory myopathies.The Paediatric Rheumatology International Trials Organization (PRINTO).The PRINTO criteria for clinically inactive disease in juvenile dermatomyositisComparison of the Utility and Validity of Three Scoring Tools to Measure Skin Involvement in Patients With Juvenile Dermatomyositis.Myositis registries and biorepositories: powerful tools to advance clinical, epidemiologic and pathogenic research.Consensus-based recommendations for the management of juvenile dermatomyositis.Improved exercise performance and increased aerobic capacity after endurance training of patients with stable polymyositis and dermatomyositisPredictors of clinical improvement in rituximab-treated refractory adult and juvenile dermatomyositis and adult polymyositis.Criteria to define response to therapy in paediatric rheumatic diseases.International consensus for a definition of disease flare in lupus.Exercise in inflammatory myopathies, including inclusion body myositis.Targeted immunotherapy trials for idiopathic inflammatory myopathies.The evidence for immunotherapy in dermatomyositis and polymyositis: a systematic review.Treatment of Juvenile Dermatomyositis: An Update.Current pharmacological treatment of idiopathic inflammatory myopathies.Time to focus on outcome assessment tools for childhood vasculitis.Physical exercise as a treatment for adult and juvenile myositis.
P2860
Q24201580-25382864-0CD2-475D-B2E1-951AC827F504Q26863125-9F4F4141-8B04-4DB0-9CC1-E8300C42ED63Q27021322-4A593AAB-640B-42B6-824B-20796581FE51Q28472665-9C58FC4B-A44A-407C-8546-58A6C5A453D6Q33670102-5F91857F-632B-4B36-BEB7-CBDBDC8651B9Q33877196-1DE03ACA-E95C-4D70-A4F3-5DDB01F2A1A3Q33962448-FB6DBA57-8453-405B-B2FB-DB3F799D4CD1Q34242363-08317649-3A45-4CD9-8224-BB494116A7E1Q34607687-DFCEA944-BA87-441D-845B-708E3DEA1A32Q34644962-4BE48431-B284-471C-8FD0-D6B5B182512CQ35009335-B325FE5E-BFB1-404E-B9C1-1026C8F55547Q35091202-1A8A7739-202A-434D-81FC-8C80A04EF175Q35206687-C4324059-73F0-4DD5-B568-1A742FDBE36AQ35755515-C11C7BF9-7F83-4C75-8771-943507A36989Q35861235-7B109EF8-DB0B-4800-AFBE-030799E0CE8FQ36013918-B9A33190-06CD-43FE-A730-790701D548F9Q36083205-359AD5AB-F726-4A3F-A1AF-7726F92CD45CQ36245680-891962A9-3A95-43AB-A9E7-9686E180FB35Q36278027-8AA7D9FC-99E1-444A-8069-55FF96531915Q36421845-4D3F3B5B-62C0-42A5-8FBE-4EEA46DE5F77Q36434501-ED05452A-2604-4303-9FE6-7F00800701D5Q36504380-A9236297-DCF0-49FD-9E1A-5562EB69BCA4Q36580468-D3ABB4CC-3C50-4541-8E00-E6824B2B1440Q36591665-EF7ECB57-DE64-4513-8CB2-7668A7134C14Q36915684-82070D10-A3FB-4BCA-8076-020E77877933Q37293030-EDB1C402-2C6C-4D6D-95CF-D64CE4E5B913Q37316551-CB200558-6A60-4798-8A9F-D4FB3ABCD583Q37368405-A3FD4A97-9D67-406C-BBD2-68B89252ECA6Q37617000-39737C2A-1DE9-4B2F-B4C5-42AAF7E072A9Q37689760-D3013BA8-6D63-4808-B06A-29C3B5D81AF5Q37704799-954D9761-CE73-4E65-9F91-3AB76F9C1F59Q37811971-95CA333A-C808-4C02-B5C5-26BBE986472CQ37819549-53BF1851-9E61-4F22-8A57-07EA3FECC89DQ37998966-9AC03987-2720-4AA3-9503-EAB66097ACF7Q38023207-52A0BA9E-21C2-4B55-B6CD-E9890F0F1697Q38572045-E4DF2C70-0298-4CC3-8F47-208EC6D272A5Q38678257-458672BE-9315-4644-8610-B317FF2D22D8Q38680762-B632F20F-239F-4139-9FFB-3F5430C99D63Q38695974-AFC2CFE6-8042-49A3-93CE-2860C1ED39C4Q38725766-EDF542AA-D29F-4DE9-B296-075A07759CAA
P2860
International consensus on preliminary definitions of improvement in adult and juvenile myositis.
description
2004 nî lūn-bûn
@nan
2004年の論文
@ja
2004年論文
@yue
2004年論文
@zh-hant
2004年論文
@zh-hk
2004年論文
@zh-mo
2004年論文
@zh-tw
2004年论文
@wuu
2004年论文
@zh
2004年论文
@zh-cn
name
International consensus on pre ...... n adult and juvenile myositis.
@ast
International consensus on pre ...... n adult and juvenile myositis.
@en
type
label
International consensus on pre ...... n adult and juvenile myositis.
@ast
International consensus on pre ...... n adult and juvenile myositis.
@en
prefLabel
International consensus on pre ...... n adult and juvenile myositis.
@ast
International consensus on pre ...... n adult and juvenile myositis.
@en
P2093
P356
P1476
International consensus on pre ...... in adult and juvenile myositis
@en
P2093
Ann M Reed
Edward H Giannini
Hermine I Brunner
International Myositis Assessment and Clinical Studies Group
Laura James-Newton
Nicola Ruperto
Peter A Lachenbruch
P304
P356
10.1002/ART.20349
P577
2004-07-01T00:00:00Z